Nyxoah’s August 5 operating update reported 180 active high-volume U.S. accounts for its Genio sleep-apnea system, including 89 activated during the second quarter. The figures describe the company’s commercial position for the quarter ended June 30.
The company said it trained 55 additional surgeons during that quarter, bringing its cumulative total to 262. It also reported 40 active sales representatives focused on 200 high-volume hypoglossal nerve stimulation accounts. These are manufacturer-reported commercial measures, rather than independent assessments of clinical performance.
U.S. quarterly net revenue reached €5.2 million, up 22 percent from the first quarter, according to the release. Nyxoah attributed broader revenue growth primarily to U.S. commercialization after Genio’s August 2025 FDA approval, alongside international growth. These figures are an earlier-quarter snapshot, not September totals.
Analysis: Expanding training and account coverage are useful indicators of supplier reach for ENT teams evaluating their sleep-surgery programs.
Go to the source.
Nyxoah’s August 5 financial and operating update ↗This brief summarizes publicly announced information. It does not establish clinical superiority or recommend a treatment.
